Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $163 from $162 and keeps an Overweight rating on the shares. Given disease severity and potential for accelerated uptake in academic centers, the firm raised its Modeyso peak second-line market share estimate to 43% from 22%, sending its peak Modeyso sales estimate up to $389M from $271M and driving its price target up by $1, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Launch of Modeyso and Advancements in Global Phase 3 Study
- Jazz Pharmaceuticals Advances Study on Epidyolex® for Seizure Disorders
- Jazz Pharmaceuticals’ Zanidatamab Study: A New Hope for Metastatic Breast Cancer?
- Jazz Pharmaceuticals Advances in HER2-positive Biliary Tract Cancer Treatment
- Jazz Pharmaceuticals’ Zanidatamab Study: A New Hope for HER2-positive Biliary Tract Cancer?